“Bimekizumab Maintenance of Response through Three Years in Patients With Moderate to Severe Plaque Psoriasis Who Responded at Week 16: Results from the BE BRIGHT Open-Label Extension Trial”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 6, Nov. 2022, p. s65, https://doi.org/10.25251/skin.6.supp.65.